The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, W.
Right arrow Articles by Hess, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, W.
Right arrow Articles by Hess, A. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Autoimmune Diseases
Hazardous Substances DB
*CYCLOSPORIN A
The Journal of Immunology, 1998, 161: 7040-7046.
Copyright © 1998 by The American Association of Immunologists

Characterization of the Pathogenic Autoreactive T Cells in Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease1

Weiran Chen, Christopher Thoburn and Allan D. Hess2

Division of Immunology and Hematopoiesis, Oncology Center, Johns Hopkins University, Baltimore, MD 21287


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Administration of the immunosuppressive drug cyclosporine after syngeneic bone marrow transplantation paradoxically elicits a systemic autoimmune syndrome resembling graft-vs-host disease (GVHD). This syndrome, termed syngeneic GVHD, is associated with the development of CD8+ cytolytic T lymphocytes that promiscuously recognize MHC class II molecules in association with a peptide from the invariant chain (CLIP). Clonal analysis reveals a major subset of cells that are pathogenic and require the N-terminal flanking region of CLIP for activation, while there is a minor subset of nonpathogenic T cells that require the C-terminal flanking region. The present studies show that pathogenic T cells produce type 1 cytokines (IL-2; IFN-{gamma}), while the nonpathogenic clones produce type 2 cytokines (IL-4; IL-10). Moreover, the repertoire of the pathogenic T cells is highly conserved with respect to Vß and V{alpha} TCR gene expression. The vast majority of clones express Vß8.5 (12/12) and V{alpha}11 (11/12). Although a limited number was evaluated, the nonpathogenic clones have only a V{alpha} restriction. Sequence analysis of the pathogenic T cell clones reveals a marked heterogeneity in the complementarity-determining region 3 domain and differential J region gene expression for both TCR {alpha}- and ß-chains. Evaluation of the specificity of these clones suggests that the functional interaction between the N-terminal flanking region of CLIP (defined by the amino acid sequence -KPVSP-) and the V region of the TCR is critical, allowing effective target cell recognition and tissue destruction in syngeneic GVHD.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Cyclosporine (CsA)3 is a widely used immunosuppressive drug that selectively suppresses T lymphocyte-dependent immune responses (1). Although CsA has potent immunosuppressive activity, this drug paradoxically disrupts the mechanisms governing self tolerance, in part by inhibiting the thymic-dependent clonal deletion of autoreactive T cells (2, 3). In fact, administration of CsA after autologous or syngeneic bone marrow transplantation (BMT) in humans and in rodent models elicits a T lymphocyte-dependent autoimmune syndrome with pathology similar to graft-vs-host disease (GVHD) occurring after allogeneic BMT (4, 5).

The onset of the CsA-induced autoaggression syndrome, termed syngeneic GVHD, is associated with the development of a highly restricted repertoire of CD8+ autoreactive T cells that promiscuously recognize MHC class II molecules (6, 7, 8, 9). MHC class II recognition occurs even though the autoreactive T cells do not have the appropriate cell surface restriction element (CD4) (6, 9). In the Lewis rat model of syngeneic GVHD, the predominant autoreactive population expresses the Vß8.3/8.5 TCR V region gene segment (8, 9). Adoptive transfer studies confirm that the CD8+ Vß8.5+ T cells that develop under the influence of CsA are responsible for initiation of this autoaggression syndrome (8).

Recent studies in humans and in rodent models reveal that the pathogenic effector T cells recognize a peptide from the MHC class II invariant chain (CLIP) presented in the context of MHC class II (9, 10). Furthermore, there appears to be a functional interaction between the TCR and the flanking regions of CLIP that extend beyond the peptide-binding domain of the MHC class II molecule, which may partially explain the promiscuous specificity of the autoreactive T cells (9). Although T cell clones can be detected that require either the N-terminal or C-terminal flanking regions in vitro, it appears that only those cells responsive to CLIP with the N-terminal flanking region are pathogenic in vivo (9). These cells, when assessed in a local graft-vs-host reaction (GVHR) assay, induce histologic changes consistent with a GVHR (i.e., apoptosis/dyskeratosis). Comparatively, clones responsive to CLIP with the C-terminal flanking region are not pathogenic in vivo. The underlying mechanisms accounting for the pathogenicity, the apparent restriction of the TCR repertoire, and the target Ag in syngeneic GVHD remain unclear.

The present studies characterize the pathogenic clones that mediate syngeneic GVHD. The results demonstrate that the pathogenic T cells produce IFN-{gamma}, whereas the nonpathogenic clones produce IL-4 and IL-10. Differential cytokine production may partially explain the pathogenic potential of the autoreactive clones responsive to CLIP with the N-terminal flanking region. Recognition of the target Ag by the pathogenic T cell clones requires an autoreactive TCR that is highly conserved with respect to both Vß and V{alpha} gene utilization. In contrast, there is significant diversity in the autoreactive TCR D and J regions that define the CDR3 domain. Moreover, peptide constructs containing the N-terminal flanking region of CLIP can be recognized by the autoreactive T cell clones. These findings, taken together, suggest that the apparent functional interaction between this flanking region and the TCR is critical in explaining the promiscuous nature of these pathogenic T cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Isolation of autoreactive T cell clones

The isolation and initial characterization of CD8+ (confirmed flow cytometrically) autoreactive T cell clones from Lewis rats with syngeneic GVHD are described in detail elsewhere (8, 9). Briefly, lymphocytes from spleens, lymph nodes, and peripheral blood from animals with biopsy-confirmed syngeneic GVHD were cultured at limiting dilution utilizing irradiated (3000 rad) syngeneic spleen cells as APCs in complete tissue culture medium containing IL-2 (10 U/ml). The clones were expanded by restimulation (every 7 to 10 days) with irradiated syngeneic spleen cells (2 x 104 cells/macrotiter well). The in vitro specificity of the effector T cells was defined using the JAM test to measure their ability to kill specifically loaded target cells (see below) (11). Pathogenicity of the autoreactive T cell clones was confirmed in vivo using a local GVHR footpad assay, as described elsewhere (9).

Cell-mediated lympholysis assay

Killing activity was assessed using a [3H]thymidine-based assay (JAM), as described by Matzinger, that measures DNA fragmentation and cell death (11). The target cells (PHA blast cells; 5–10 x 106) were pulsed with 2.5 µCi/ml [3H]thymidine for 18 h and washed three times before assay. Graded numbers (1 x 104 to 1 x 105) of the effector T cell clones and the target cells (5 x 103) were coincubated for 4 h before harvest. Variability between replicate cultures averaged less than 5%.

Peptides

The sequences of parent CLIP (aa 82–103) and the peptides utilized in the present studies are given in Table IGo and include the truncated variants of CLIP containing just the MHC class II-binding domain (aa 90–100) or this domain with either the N-terminal or C-terminal flanking region (aa 86–100, 90–104), CLIP with inverted flanking regions, an MHC class II-binding allospecific peptide from the immunogenic region of MHC RT1.A, and chimeric constructs of this allopeptide with the N-terminal and C-terminal flanking regions of CLIP (12, 13). The peptides, chemically synthesized and purified by high pressure liquid chromatography, were obtained from Quality Controlled Biochemicals (Hopkinton, MA). The peptides (>92% purity) were diluted to 10 µM in RPMI 1640 prior to loading MHC class II-positive lymphoblasts, as previously described (9). Previous dose-response studies revealed that maximal enhancement of killing was achieved by pretreating the target cells with 1 µM peptide (9).


View this table:
[in this window]
[in a new window]
  		Table I. Truncated and modified MHC class II invariant chain peptides

 
RNA preparation

RNA was extracted and purified with Trizol reagent (Life Technologies, Gaithersburg, MD), according to the protocol provided by the manufacturer. In brief, the cloned T cells were harvested and washed twice in PBS. Cell lysate was prepared from 5 x 104 cells in 500 µl Trizol reagent with adequate mixing. After adding 100 µl chloroform, the solution was well mixed and centrifuged. The supernatant was collected and extracted once with chloroform. RNA was precipitated with 2-propanol and rinsed with 70% ethanol. Purified RNA was dissolved in 20 µl diethyl-pyrocarbonate-treated distilled water.

Reverse-transcription PCR

cDNA was prepared with Ready-To-Go reverse-transcription (RT) kit (Pharmacia Biotech, Piscataway, NJ), according to the protocol provided by the manufacturer. RT reaction was performed in a total volume of 33 µl and primed with random hexamer. For each sample, two RT reactions were conducted, the cDNA products were pooled, and 2 µl cDNA was used for PCR. Oligonucleotide primers for routine PCR analysis of Vß and V{alpha} gene usage have been previously described (8, 14, 15, 16). Primers used for PCR analysis of cytokines and PCR amplification before TCR sequencing are summarized in Table IIGo (17). For cytokine analysis, actin was also amplified as a semiquantitative indicator of cDNA used in each reaction. The PCR was conducted in a total volume of 25 µl containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 200 µM dNTP, 100 nM each of the primers, and 5 U Taq DNA polymerase (Life Technologies). The thermal cycler (Perkin-Elmer, Branchburg, NJ) was programmed as 95°C x 1 min, 60°C x 1 min, 72°C x 1 min, 30 cycles. The PCR products were extracted with chloroform, and electrophoresis was performed on a 1.5% agarose gel. Gels were stained with ethidium bromide to visualize the bands.


View this table:
[in this window]
[in a new window]
  		Table II. Oligonucleotides for PCR analysis of cytokines and TCR sequencing

 
Cloning and sequencing of the PCR products

For each T cell clone, three PCR reactions were conducted and the PCR products were pooled for cloning. PCR products were cloned into the pT7 blue plasmid vector by using the pT7 Blue Perfectly Blunt Cloning Kit (Novagen, Madison, WI). DNA sequence was determined by dideoxy chain termination method and the Sequenase Version 2.0 DNA Sequencing Kit (Amersham Life Science, Cleveland, OH). The sequencing reaction was primed by the -40 Primer supplied by the kit. The TCR genes utilized by the clones were identified by comparison with previously reported TCR gene sequences (14, 16, 18).

Immunopathology

Tissues were analyzed for expression of MHC class II and CLIP by immunohistochemistry, as previously described (19). Briefly, frozen sections were incubated with mouse anti-rat MHC class II mAb (Serotec; Harlan Bioproducts for Science, Indianapolis, IN) or with affinity-purified (CLIP-Sepharose columns) rabbit anti-rat CLIP (developed by Quality Controlled Biochemicals, Hopkinton, MA). The specificity of these Abs has been previously reported (9). The activity of the anti-CLIP Ab could be inhibited specifically with 10 µM of peptide. Controls consisted of sections incubated with normal mouse serum or prebled rabbit IgG. After 60 min of incubation, the sections were washed in Tris-buffered saline (pH 8.2) with 1% milk (TBS-milk) and incubated (30 min) with biotinylated F(ab')2 goat anti-mouse IgG or F(ab')2 goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA), respectively. Subsequently, the sections were washed with TBS-milk, incubated for 60 min with avidin-alkaline phosphatase, and developed with Fast Red. The sections were counterstained with hematoxylin.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Cytokine profiles of the pathogenic T cell clones

Previous studies in our laboratory indicated that the autoreactive T cells that mediate syngeneic GVHD recognize CLIP in the context of MHC class II (9). Discrete subsets of these T cells exist that require not only the MHC class II-binding domain of CLIP, but also flanking regions that extend outside of the MHC peptide pocket. Interestingly, only the T cell clones that require the N-terminal flanking region of CLIP, which represent the majority (>75%) of CLIP-reactive T cell clones, were pathogenic in vivo (9).

Semiquantitative PCR was used to examine the cytokine production of the pathogenic T cell clones. The RNA was isolated from the clones 9 days after their last stimulation with irradiated APCs. To verify that equal amounts of RNA were used in each RT-PCR reaction, actin was also amplified along with the target cytokines (IL-2, IL-4, IL-10, IFN-{gamma}). Fig. 1Go shows the cytokine profiles of the T cell clones. All five pathogenic clones produced readily detectable mRNAs for IL-2 and IFN-{gamma}. Neither mRNAs for IL-4 nor IL-10 were detected from the pathogenic clones. In contrast, the three nonpathogenic clones produced large amounts of IL-4 and IL-10 cytokine mRNA transcripts with no detectable mRNA transcripts for IL-2 or IFN-{gamma}. As an internal control, cytokine mRNA transcripts could not be detected from APCs cultured alone for 9 days (data not shown). Ten additional clones of similar specificity (8 N-terminal restricted; 2 C-terminal restricted) revealed an identical cytokine profile with IFN-{gamma} and IL-2 produced by the N-terminal restricted clones, and with IL-4 and IL-10 produced by the C-terminal restricted clones. Moreover, stimulation of the pathogenic clones with a truncated variant of CLIP containing the N-terminal flanking region resulted in a significant increase in IFN-{gamma} mRNA production after 3 h in culture, as shown in Fig. 2Go. Stimulation with the variant containing the C-terminal flanking region or just the MHC class II-binding domain of CLIP did not induce up-regulation of IFN-{gamma} mRNA.



View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 1. Analysis of cytokine production by RT-PCR. The pathogenic and nonpathogenic clones were analyzed for production of type 1 (IL-2, IFN-{gamma}) and type 2 (IL-4, IL-10) cytokines by RT-PCR. Actin was also amplified in each reaction as an internal control (upper band). Molecular weight standards are shown in the left outermost lane.

 


View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 2. Stimulation of IFN-{gamma} production by truncated variants of CLIP. T cells restricted by the N-terminal flanking region of CLIP were stimulated for 3 h of 37°C with truncated variants of CLIP (10 µM) that included just the MHC class II-binding domain or this domain with either the N-terminal or C-terminal flanking regions of CLIP. The control consisted of cells cultured with media. After stimulation, the cells were analyzed for IFN-{gamma} mRNA by RT-PCR. Actin was also amplified in each reaction as an internal control. MW-STD are m.w. standards.

 
The capacity to make IFN-{gamma} implies that the pathogenic T cells are able to induce up-regulation of MHC class II-CLIP, the target Ag. Since the tongue is one of the primary target tissues for syngeneic GVHD in the rat, the expression of MHC class II and CLIP was assessed in animals with active disease. Histopathologic examination revealed that there is a marked up-regulation of MHC class II molecules in the tongue during active disease, as shown in Fig. 3GoA. Staining is most intense at the epidermal-dermal junction of the mucosal epithelium. Similarly, pronounced expression of CLIP was also detected in this region of the epithelium (Fig. 3GoC). Inflammatory mononuclear cells infiltrating the tissue also stained with the anti-MHC class II and anti-CLIP Abs, and probably include dendritic cells, monocytes, and activated T cells that express MHC class II (6, 7, 9, 20, 21, 22). Controls (normal mouse serum or rabbit-prebled IgG) showed no significant staining (Fig. 3Go, B and D). Examination of tissue from normal animals revealed no significant staining with either the anti-MHC class II or anti-CLIP Abs (data not shown), and is consistent with the results from previous studies indicating that MHC class II gene products are not expressed in normal, nonstimulated epithelial cells (20, 21, 22).



View larger version (133K):
[in this window]
[in a new window]
  		FIGURE 3. Expression of MHC class II and CLIP. Tongue, a major target organ for syngeneic GVHD, was assessed for expression of MHC class II and CLIP during active disease. The tissue was harvested upon the onset of syngeneic GVHD and stained with mouse anti-rat MHC class II mAb (A) or affinity-purified rabbit anti-rat CLIP Ab (C). Controls consisted of tissue stained with normal mouse serum (B) or rabbit-prebled IgG (D). Ab staining was detected with avidin alkaline phosphatase (Fast Red stain) after counterstaining with biotinylated F(ab')2 goat anti-mouse or anti-rabbit IgG. Original magnification x100.

 
TCR analysis of the pathogenic T cell clones

In the current study, pathogenic T cell clones were typed for TCR usage by PCR. As shown in Table IIIGo, all of the pathogenic clones (clones 1, 2, 3, 6, and 12) were Vß8.5, while four of these clones expressed V{alpha}11. The remaining clone was V{alpha}10+. The three nonpathogenic clones (clones 18, 71, and 77) were all V{alpha}10+, but used Vß2, 5, and 8.1, respectively. Seven additional N-terminal restricted clones expressed Vß8.5 and V{alpha}11. Since the TCR restriction of the pathogenic clones appeared highly conserved, their TCRs were sequenced to further characterize their clonotypic receptors.


View this table:
[in this window]
[in a new window]
  		Table III. Expression of V{alpha} and Vß TcR Genes in autoreactive T Cells from animals with syngeneic GVHD1

 
The representative sequence of the N-D-N domain and Jß gene utilization of the TCR ß-chain from each T cell clone are given in Fig. 4Go. Among the five pathogenic clones, clones 1 and 2 were identical, using the same N-D-N region and Jß2.6 segments. No similarities in the N-D-N or Jß regions were found among the other three Vß chains of the pathogenic clones (clones 3, 6, and 12). To explore the possibility that Jß2.6 is preferentially used by the Vß8.5+/V{alpha}11+ T cell clones, seven additional Vß8.5+/V{alpha}11+ T cell clones with the N-terminal restricted specificity were sequenced. Jß2.6 was used by five of the seven clones (clones A, B, C, D, and E), while the other two clones expressed different J region genes. Also, there was no homology in the N-D-N for these seven clones. Vß8.5 identity for all clones was confirmed during sequencing. Sequences of the {alpha}-chain from a select number of Vß8.5+V{alpha}11+ pathogenic T cell clones were also assessed. As shown in Fig. 5Go, each clone used a different J{alpha} segment. No significant homology was found in the N-D-N region among the four clones, although valine and glycine were found at high frequency.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 4. Analysis of the TCR ß-chain. The TCR ß-chain was sequenced from 12 CLIP N-terminal restricted clones. The DNA sequence was converted to amino acid sequence. The amino acid sequence of the CDR3 domain and the Jß gene utilization are given for each clone. Sequencing also confirmed Vß8.5 identity for these 12 clones. *, Clones numerically designated were confirmed to be pathogenic in vivo (9). The other clones (A–F) were not evaluated for pathogenicity.

 


View larger version (6K):
[in this window]
[in a new window]
  		FIGURE 5. Analysis of the TCR {alpha}-chain. The TCR {alpha}-chain was sequenced from four pathogenic T cell clones. The amino acid sequence was derived from the DNA sequence. The sequence within the CDR3 domain and J{alpha} gene utilization are given for each clone. Sequencing also confirmed V{alpha}11 identity for these four clones.

 
Specificity and the N-terminal flanking region of CLIP

Previous studies in our laboratory suggested that there may be a functional interaction between the N-terminal flanking region of CLIP and the V region of the TCR ß-chain at or near the SEB binding site (9). This interaction could explain the bias in the TCR repertoire to cells expressing a V region gene that allows responsiveness to SEB (8, 9, 23). A series of studies was conducted to evaluate the importance of this N-terminal flanking region. Ten clones were randomly selected from the total pools of lytic clones with either N-terminal or C-terminal sp. act. Fig. 6GoA illustrates the lytic profile for 10 representative pathogenic clones. Target cells loaded with the MHC class II-binding domain of CLIP were not effectively killed by the pathogenic clones at limiting E:T cell ratios (5:1). Killing was maximal when target cells were loaded with CLIP containing the N-terminal flanking region. In contrast, killing was negligible when CLIP containing the C-terminal flanking region was loaded. A reciprocal pattern was observed with 10 C-terminal restricted, nonpathogenic clones (Fig. 6GoB). To assess the relative spatial importance of the N-terminal and C-terminal flanking regions, target cells were loaded with a construct of CLIP that had the N- and C-terminal flanking regions inverted. Neither the pathogenic T cell clone nor the nonpathogenic clones killed the target cells loaded with the dyslexic peptide. The effect of adding these flanking regions to an MHC class II-binding allopeptide was also assessed. The pathogenic T cell clones did not kill the cells loaded with the allopeptide. In contrast, cells loaded with the chimeric allopeptide containing the N-terminal flanking region were recognized by the pathogenic T cell clones. The level of killing was comparable with cells loaded with CLIP containing the N-terminal flanking region. On the other hand, addition of the C-terminal flanking region to the allopeptide did not have a similar effect for the C-terminal restricted nonpathogenic clones.



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 6. Specificity of the autoreactive T cell clones. N-terminal (A) and C-terminal (B) restricted autoreactive T cell clones were assessed for their ability to kill syngeneic lymphoblasts loaded with truncated (tr) or modified variants of CLIP, and an MHC class II-binding allopeptide or chimeric constructs of this peptide modified with the N-terminal or C-terminal flanking regions of CLIP. E:T ratio was 5:1. The results reflect the percent specific killing (mean ± SE) of 10 representative N-terminal and C-terminal restricted clones.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Syngeneic GVHD is mediated by a highly conserved repertoire of CD8+Vß8.5+ T cells that promiscuously recognize MHC class II (6, 7, 8, 9, 24). Recognition of MHC class II molecules by the autoreactive T cells is facilitated by the presentation of a peptide from the invariant chain, CLIP (9, 10). Essential for the promiscuous recognition of MHC class II independent of the CD4 accessory molecule is the interaction between the N-terminal flanking region of CLIP and the Vß segment of the TCR (9, 24). Clonal analysis, however, reveals two discrete subsets of T cells that require either the N-terminal or the C-terminal flanking region (9). Although both subsets of cells can functionally recognize target cells in vitro, surprisingly, only the cells that require the N-terminal flanking region of CLIP are pathogenic in vivo. These cells induced histologic changes consistent with a GVHR (with marked epithelial cell destruction and dyskeratosis) (25). In contrast, clones requiring the C-terminal flanking region of CLIP were nonpathogenic, as assessed in this in vivo model. Analysis of cytokine production revealed that the pathogenic clones produced IFN-{gamma} and IL-2, type 1 cytokines. Comparatively, the nonpathogenic clones produced type 2 cytokines (IL-4, IL-10).

The production of type 1 cytokines may underlie, in part, the pathogenicity of the N-terminal restricted clones. Release of IFN-{gamma} in the target tissue would lead to the up-regulation of the MHC class II-CLIP complex, the target Ag of the pathogenic clones. In fact, the present studies demonstrate that MHC class II and CLIP are up-regulated in the target tissue during active syngeneic GVHD. A similar mechanism occurs during acute GVHD following allogeneic BMT, leading to the up-regulation of MHC class II in the target tissue (20, 21, 22). Interestingly, recent evidence indicates that there is discoordinate surface expression of IFN-{gamma}-induced MHC class II proteins in nonprofessional APCs (26). Following IFN-{gamma} stimulation, the production of DM, the class II molecule that facilitates displacement of CLIP with nominal peptide (27), is delayed relative to expression of DR and the coordinated expression of the invariant chain (26, 27). Moreover, there is an absence of DM and DR colocalization, also leading to a failure or delay in the exchange of CLIP for nominal peptides. In effect, cell surface MHC class II expression on nonprofessional APCs after exposure to IFN-{gamma} would be largely associated with CLIP, which is critical for stabilization of the MHC class II molecule (12, 13, 25, 26). Thus, IFN-{gamma}-induced up-regulation of the MHC class II-CLIP complex enhances the potential for target tissue destruction by the autoreactive T cells that mediate syngeneic GVHD.

The role of the C-terminal restricted, nonpathogenic clones in syngeneic GVHD remains unclear. The nonpathogenic clones appear to express an array of Vß molecules, while there is a marked restriction to Vß8.5 in the pathogenic T cell subset (8, 9). These clones produce IL-4 and IL-10, which do not actively promote up-regulation of MHC class II in the target tissue. In this regard, allospecific CD8+ cells that secrete type 2 cytokines do not mediate acute GVHD (28). On the other hand, the C-terminal restricted subset of cells may promote the development of the chronic phase of syngeneic GVHD, characterized by fibrosis and sclerosis (20). Consistent with this hypothesis is the observation that cells secreting type 2 cytokines play a critical role in the pathogenesis of chronic GVHD after allogeneic BMT (29, 30). Alternatively, the C-terminal restricted, nonpathogenic clones may represent a subset of regulatory T cells that may modify the response of the pathogenic T cells. Current studies are attempting to define the role of this subset in vivo.

The pathogenic T cells that mediate syngeneic GVHD not only have a unique specificity for the MHC class II-CLIP complex, but also are restricted in their use of TCR V region genes (8, 15). Molecular analysis of the TCR of the pathogenic T cell clones reveals a remarkable conservation with respect to V{alpha} and Vß gene utilization. Virtually all of the pathogenic clones express the Vß8.5 and V{alpha}11 TCR molecules. Interestingly, these same V region components are utilized by the CD4+ autoreactive T cell subset in syngeneic GVHD (8, 24, 31). This autoreactive T cell subset, which also has specificity for CLIP, is not pathogenic per se, but can amplify the activity of the CD8+ pathogenic T cells (30). On the other hand, sequence analysis of the CD8+ clones reveals marked heterogeneity in the CDR3 domains of both V{alpha} and Vß chains that, in part, define the peptide specificity of the TCR. It appears that multiple CDR3 constructs can be used to recognize CLIP since there is degenerate recognition, a "looseness of fit" between the TCR and the MHC class II- peptide complex (32). In fact, recent evidence indicates that specific T cell clones can recognize a multitude of peptides presented by MHC molecules (33, 34). On the other hand, loading the truncated variant containing just the MHC class II-binding domain of CLIP (35) was insufficient to allow killing of the target cells at low E:T cell ratios. Killing of target cells loaded with this truncated variant of CLIP could only be demonstrated at much higher E:T cell ratios with a limited efficiency (50–60% maximum killing), indicating specificity for the MHC class II-binding domain of CLIP, but with weak affinity (9). These data, however, suggest that effective recognition requires an additional interaction, outside of the MHC-binding domain.

The N-terminal flanking region of CLIP, which extends beyond the terminus of the peptide-binding groove of MHC class II molecules, plays a major role in recognition (35, 36, 37). Previous studies suggest that the N-terminal flanking region interacts with MHC class II molecules at or near the SEB binding site and can stabilize peptide binding (38, 39). On the other hand, the hypothesis that effective recognition of the MHC class II-CLIP complex by the pathogenic T cells requires an interaction of this flanking region with the Vß chain of the TCR outside of the CDR3 domain, is based on the findings that SEB pretreatment of the autoreactive T cells inhibits their lytic function (9), and that the N-terminal flanking region of CLIP prevents the SEB-dependent ligation of the TCR V region segment with MHC class II molecules (40). The results from the current studies indicate that this interaction is quite important, and defines the specificity of the pathogenic T cells. Loading a chimeric construct of an MHC class II-binding allopeptide with the N-terminal flanking region of CLIP (consisting of the KPVSP amino acid sequence) promoted effective recognition of the target cells. Target cells loaded with the unmodified allopeptide could not be killed even at high E:T ratios (9), suggesting that this interaction may override inadequate complementarity between the CDR3 domain of the TCR and the peptide. Recognition of the peptide bound in the groove of MHC class II by the autoreactive T cells appears, at best, to be secondary to that of the interaction between the N-terminal flanking region of CLIP and the TCR V region. Furthermore, the results from the present studies suggest that the spatial orientation of this flanking region is also of critical importance. Inversion of the flanking regions on CLIP does not allow for recognition and killing of the target cells. These data are consistent with recent studies indicating that T cell recognition of Ag requires the proper orientation of the TCR relative to the MHC class II-peptide complex. (41) The CDR1 domains of the TCR {alpha}- and ß-chains must be appropriately aligned with the {alpha}- and ß-chains of MHC class II molecules to allow recognition of the peptide. Therefore, it appears that the N-terminal flanking region must also be in alignment with a specific V region component of the TCR. This interaction of the flanking region on CLIP, when presented in the context of MHC class II, appears to be near a contact site between the Vß segment of the TCR, the MHC class II determinant, and SEB. Such a mechanism may explain the V region restriction of the autoreactive T cell repertoire in syngeneic GVHD, in particular to a Vß gene that allows responsiveness to SEB (8, 9, 23, 42). The conserved V{alpha} segment may also play a significant role since recent studies indicate that the TCR {alpha}-chain can influence the response to superantigens (43). Nevertheless, the interaction between this flanking region of CLIP and the clonotypic Ag receptor would strengthen the avidity of the TCR-CLIP-MHC complex and may bypass the requirement for the appropriate cell surface accessory molecule (i.e., CD4).

Comparatively, the nonpathogenic clones are restricted by the C-terminal flanking region of CLIP. Although the analysis was limited, these clones express an array of Vß molecules, but appear to share a common V{alpha} element. Whether a similar interaction occurs between the C-terminal flanking region of CLIP and the V region elements of the TCR is currently under investigation.

In summary, the results of the present studies reveal that syngeneic GVHD is mediated by a highly restricted subset of T cells that produce type 1 cytokines. Moreover, the interaction between the N-terminal flanking region of CLIP and the autoreactive TCR is critically important, allowing for effective target cell recognition and tissue destruction. Interestingly, analysis of an autoaggression syndrome in humans occurring after clinical autologous BMT and CsA treatment reveals virtually identical autoimmune mechanisms (10). The analogous promiscuous recognition of MHC class II molecules and dependence on CLIP of the autoreactive T cells demonstrate the fundamental importance of this mechanism.


   Acknowledgments
 
We acknowledge Ms. Kathy Suttka for her excellent secretarial assistance, and Dr. Teresa Pfaff-Ameese for her assistance with the immunopathology. We also thank Dr. Ephraim Fuchs for his critical review of this manuscript.


   Footnotes
 
1 This work was supported by Grants AI 24319, HL 58091, and CA 15396 from the National Institutes of Health. Back

2 Address correspondence and reprint requests to Dr. Allan D. Hess, Oncology Center, Johns Hopkins University, 600 N. Wolfe Street, Room 3-127, Baltimore, MD 21287-8985. Back

3 Abbreviations used in this paper: CsA, cyclosporine; aa, amino acid; BMT, bone marrow transplantation; CDR, complementarity-determining region; CLIP, MHC class II invariant chain peptide; GVHD, graft-vs-host disease; GVHR, grraft-vs-host reaction; RT, reverse-transcription; SEB, staphylococcal enterotoxin B. Back

Received for publication June 22, 1998. Accepted for publication August 17, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kahan, B. D.. 1989. Cyclosporine. N. Engl. J. Med. 21:1725.
  2. Jenkins, M. K., R. H. Schwartz, D. M. Pardoll. 1988. Effects of cyclosporin A on T cell development and clonal deletion. Science 241:1655.[Abstract/Free Full Text]
  3. Urdahl, K. B., D. M. Pardoll, M. K. Jenkins. 1994. Cyclosporin A inhibits positive selection and delays negative selection in {alpha}/ß TCR transgenic mice. J. Immunol. 152:2853.[Abstract]
  4. Glazier, A., P. J. Tutschka, E. R. Farmer, G. W. Santos. 1983. Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow reconstitution. J. Exp. Med. 158:1.[Abstract/Free Full Text]
  5. Hess, A. D., C. J. Thoburn. 1997. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-vs-host disease. Immunol. Rev. 157:111.[Medline]
  6. Hess, A. D., L. Horwitz, W. E. Beschorner, G. W. Santos. 1985. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J. Exp. Med. 161:718.[Abstract/Free Full Text]
  7. Hess, A. D., L. R. Horwitz, M. K. Laulis. 1993. Cyclosporine induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin. Immunol. Immunopathol. 69:341.[Medline]
  8. Fischer, A. C., P. P. Ruvolo, R. Burt, L. R. Horwitz, E. C. Bright, J. M. Hess, W. E. Beschorner, A. D. Hess. 1995. Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft-versus-host disease: a highly conserved repertoire mediates autoaggression. J. Immunol. 154:3713.[Abstract]
  9. Hess, A. D., C. Thoburn, L. Horwitz. 1998. Promiscuous recognition of major histocompatibility class II determinants in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 65:785.[Medline]
  10. Hess, A. D., E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, M. J. Kennedy. 1997. Specificity of effector lymphocytes in autologous graft-vs-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 89:2203.[Abstract/Free Full Text]
  11. Matzinger, P.. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.[Medline]
  12. Freisewinkel, I. M., K. Schench, N. Koch. 1993. The segment of the invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc. Natl. Acad. Sci. USA 90:9703.[Abstract/Free Full Text]
  13. Fangmann, J., R. Dalchau, G. J. Sawyer, C. A. Priestley, J. W. Fabre. 1992. T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur. J. Immunol. 22:1525.[Medline]
  14. Gold, D. P., D. Bellgrau. 1991. Identification of a limited T-cell receptor ß-chain variable region repertoire associated with diabetes in the BB rat. Proc. Natl. Acad. Sci. USA 88:9888.[Abstract/Free Full Text]
  15. Hess, A., P. Ruvulo, A. Fischer, L. Horwitz, E. Bright, C. Thoburn. 1997. Characterization of the V{alpha}/Vß autoreactive T-cell repertoire in syngeneic graft-vs-host disease. Transplant. Proc. 29:709.[Medline]
  16. Shirwan, H., M. Ohanjanian, G. Burcham, L. Makowaka, D. V. Cramer. 1993. Structure and diversity of rat T cell receptor {alpha}-chain genes. J. Immunol. 150:2295.[Abstract]
  17. Siegling, A., M. Lehmann, C. Platzer, F. Emmrich, H.-D. Volk. 1994. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J. Immunol. Methods 177:23.[Medline]
  18. Williams, C. B., E. P. Blankenhorn, K. E. Byrd, G. Levinson, G. A. Gutman. 1991. Organization and nucleotide sequence of the rat T cell receptor ß-chain complex. J. Immunol. 146:4406.[Abstract]
  19. Ibrahim, S., D. V. Dawson, P. Van Trigt, F. Sanfillippo. 1993. Differential infiltration by CD45RO and CD45RA subsets of T cells associated with human heart allograft rejection. Am. J. Pathol. 142:1794.[Abstract]
  20. Beschorner, W. E., C. A. Shinn, A. C. Fischer, G. W. Santos, A. Hess. 1988. Cyclosporine-induced pseudo GVHD in the early post-cyclosporine period. Transplantation 46:(Suppl.):112S.[Medline]
  21. Beschorner, W. E., P. J. Tutschka, G. W. Santos. 1982. Chronic GVHD in the rat chimera. I. Clinical presentation, hematology, histology, and immunopathology in the long term chimeras. Transplantation 33:393.[Medline]
  22. Volc-Platzer, B., K. Rappersberger, I. Mosberger, W. Hinterberger, W. Emminger-Schmidmeier, T. Radaszkiewicz, K. Wolff. 1988. Sequential immunohistologic analysis of the skin following allogeneic bone marrow transplantation. J. Invest. Dermatol. 91:162.[Medline]
  23. Gold, D. P., C. D. Surh, K. S. Sellins, K. Schroder, J. Sprent, D. B. Wilson. 1994. Rat T cell responses to superantigens. II. Allelic differences in Vß 8.2 and Vß 8.5 ß chains determine responsiveness to staphylococcal enterotoxin B and mouse mammary tumor virus-encoded proteins. J. Exp. Med. 179:63.[Abstract/Free Full Text]
  24. Hess, A. D., C. Thoburn, E. Bright, L. Horwitz. 1997. Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide. Transplant. Proc. 29:725.[Medline]
  25. Beschorner, W. E., P. J. Tutschka, G. W. Santos. 1982. Sequential morphology of GVHD in the rat radiation chimera. Clin. Immunol. Immunopathol. 22:203.[Medline]
  26. Muczynski, K. A., S. K. Anderson, D. Pious. 1998. Discoordinate surface expression of IFN-{gamma}-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization. J. Immunol. 160:3207.[Abstract/Free Full Text]
  27. Cresswell, P.. 1996. Invariant chain structure and MHC class II function. Cell 84:505.[Medline]
  28. Fowler, D. H., J. Breglio, G. Nagel, M. A. Eckhaus, R. E. Gress. 1996. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J. Immunol. 157:4811.[Abstract]
  29. Parkman, R.. 1985. Clonal analysis of murine graft-versus-host disease. I. Phenotypic and functional of T lymphocyte clones. J. Immunol. 136:3542.
  30. Parkman, R.. 1990. Clonal analysis of graft-vs-host disease. S. J. Burakoff, and H. J. Deeg, and J. Ferrara, and K. Atkinson, eds. Graft-vs-Host Disease 51. Marcel Dekker, New York.
  31. Hess, A. D., A. C. Fischer, W. E. Beschorner. 1990. Effector mechanisms in cyclosporin A induced syngeneic graft-versus-host disease: role of CD4+ and CD8+ T lymphocyte subsets. J. Immunol. 145:526.[Abstract]
  32. Hemmer, B., M. Vergelli, C. Pinilla, R. Houghten, R. Martin. 1998. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today 19:163.[Medline]
  33. Threlkeld, S. C., P. A. Wentworth, S. A. Kalamo, B. M. Wilkes, D. J. Ruhl, E. Keogh, J. Sidney, S. Southwood, B. D. Walker, A. Sette. 1997. Degenerate and promiscuous recognition by CTL of peptide presented by the MHC class I A3-like superfamily. J. Immunol. 159:1648.[Abstract]
  34. Vergelli, M., B. Hemman, M. Kalbus, A. B. Vogt, N. Ling, P. Conlon, J. E. Coligan, H. McFarland, R. Martin. 1997. Modification of peptide ligands enhancing T cell responsiveness implies large numbers of stimulatory ligands for autoreactive T cells. J. Immunol. 158:3746.[Abstract]
  35. Ghosh, P., M. A. Maya, E. Mellins, D. C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: clip bound to HLA-DR3. Nature 378:457.[Medline]
  36. Malcherek, G., V. Gnau, G. Jung, H. G. Rammensee, A. Melms. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex class II molecules. J. Exp. Med. 181:527.[Abstract/Free Full Text]
  37. Freisewinkel, I. M., K. Schneck, N. Koch. 1993. The segment of the invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc. Natl. Acad. Sci. USA 90:9703.
  38. Vogt, A. B., L. J. Stern, C. Amshoff, B. Dobberstein, G. J. Hammerling, H. Kropshofer. 1995. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J. Immunol. 155:4757.[Abstract]
  39. Siebenkotben, I. M., C. Carotens, N. Koch. 1998. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes. J. Immunol. 160:3355.[Abstract/Free Full Text]
  40. Ericson, M. L., M. Sundstrom, D. M. Sansom, D. J. Charron. 1994. Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. J. Biol. Chem. 269:25538.
  41. Hong, S. C., D. B. Sant’Angelo, B. N. Dietel, R. Medzhitov, S. T. Yoon, P. G. Waterbury, Jr C. A. Janeway. 1997. The orientation of a T cell receptor to its MHC class II: peptide ligands. J. Immunol. 159:4395.[Abstract]
  42. Fu, Y., P. A. Villas, E. P. Blankenhorn. 1991. Genetic control of rat T-cell response to Staphylococcus aureus enterotoxins. Immunology 75:484.
  43. Deckhut, A. M., Y.-H. Chien, M. A. Blackman, D. L. Woodland. 1994. Evidence for a functional interaction between the ß-chain of MHC class II and the T cell receptor {alpha}-chain during recognition of a bacterial superantigen. J. Exp. Med. 180:1921.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. S. Bryson, L. Zhang, S. W. Goes, C. D. Jennings, B. E. Caywood, S. L. Carlson, and A. M. Kaplan
CD4+ T Cells Mediate Murine Syngeneic Graft-versus-Host Disease-Associated Colitis
J. Immunol., January 1, 2004; 172(1): 679 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. M. Flanagan, C. D. Jennings, S. W. Goes, B. E. Caywood, R. Gross, A. M. Kaplan, and J. S. Bryson
Nitric oxide participates in the intestinal pathology associated with murine syngeneic graft-versus-host disease
J. Leukoc. Biol., October 1, 2002; 72(4): 762 - 768.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?
Blood, February 1, 2002; 99(3): 768 - 784.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. W. Langerak, R. van den Beemd, I. L. M. Wolvers-Tettero, P. P. C. Boor, E. G. van Lochem, H. Hooijkaas, and J. J. M. van Dongen
Molecular and flow cytometric analysis of the V{beta} repertoire for clonality assessment in mature TCR{alpha}{beta} T-cell proliferations
Blood, July 1, 2001; 98(1): 165 - 173.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Xia, J. Goebels, O. Rutgeerts, M. Vandeputte, and M. Waer
Transplantation Tolerance and Autoimmunity After Xenogeneic Thymus Transplantation
J. Immunol., February 1, 2001; 166(3): 1843 - 1854.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Nikolic, G. Zhao, K. Swenson, and M. Sykes
A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT
Blood, August 1, 2000; 96(3): 1166 - 1172.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, W.
Right arrow Articles by Hess, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, W.
Right arrow Articles by Hess, A. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Autoimmune Diseases
Hazardous Substances DB
*CYCLOSPORIN A

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS